Â÷¼¼´ë ´ç´¢º´ Ä¡·á ¹× ¾à¹°Àü´Þ ½ÃÀå : Á¦Ç° À¯Çüº°, Àα¸Åë°èº°, ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Next Generation Diabetes Therapy and Drug Delivery Market by Product Type, Demographic (Adult Population, Child Population ), Indication, End User (Diagnostic/Clinics, Intensive Care Units, Home Healthcare), and Region 2025-2033
»óǰÄÚµå : 1675351
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 149 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,351,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,802,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,253,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Â÷¼¼´ë ´ç´¢º´ Ä¡·á¡¤¾à¹°Àü´Þ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 112¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀåÀÌ 370¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³â¿¡ 13.52%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ´ç´¢º´, ƯÈ÷ 2Çü ´ç´¢º´ÀÇ À¯º´·ü »ó½Â, Áö¼ÓÀû ±â¼úÀÇ Áøº¸, ³ë³â Àα¸ÀÇ Áõ°¡°¡ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù.

Â÷¼¼´ë ´ç´¢º´ Ä¡·á ¹× ¾à¹°Àü´Þ ¹æ¹ýÀº Àν¶¸°À» ȯÀÚÀÇ Ã¼³»·Î Àúħ½ÀÀûÀ¸·Î µµÀÔÇÏ´Â µ¥ ÁßÁ¡À» µÎ¾î ÁÖ»ç¹Ù´ÃÀÇ ºó¹øÇÑ »ç¿ëÀ¸·Î ÀÎÇÑ ÇǺΠÀÚ±ØÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ÀÌ È¯ÀÚ Ä£È­ÀûÀÎ Á¢±Ù ¹æ½ÄÀº ¿þ¾î·¯ºí ¼¾¼­, ¸¶ÀÌÅ©·Î´Ïµé, ÈíÀÔ Àν¶¸°°ú °°Àº Çõ½ÅÀûÀÎ ±â¼úÀ» Ȱ¿ëÇÏ¿© È¿°úÀûÀ¸·Î Áúº´À» °ü¸®Çϰí ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛ(CGMS), Àΰø ÃéÀå, Àν¶¸° ÆÐÄ¡¿Í °°Àº ÷´Ü Ä¡·á¹ýµµ ´ç´¢º´ °ü·Ã ÇÕº´ÁõÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ´Â Ç÷´ç °ü¸®¸¦ °³¼±Çϱâ À§ÇØ Ã¤Åõǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ë·® °è»êÀÌ ¿ëÀÌÇϰí, ½Ç½Ã°£À¸·Î Ç÷´ç ¼öÄ¡¸¦ È®ÀÎÇÒ ¼ö ÀÖÀ¸¸ç, ÅëÁõ ¾øÀÌ Àν¶¸°À» ü³»¿¡ Åõ¿©ÇÒ ¼ö ÀÖÀ¸¸ç, Åõ¿© ½Ã°£ À¯Áö¿¡µµ µµ¿òÀÌ µË´Ï´Ù. ÀÌ Ä¡·á¹ý°ú ¾à¹°Àü´ÞÀÇ ÀåÁ¡Àº ȯÀÚÀÇ ¿¹ÈÄ °³¼±, Ä¡·á È¿À²¼º Çâ»ó, ȯÀÚÀÇ ´ç´¢º´ °ü¸® ºÎ´ã ÃÖ¼ÒÈ­, º¸´Ù Ÿ±êÆÃµÈ Ä¡·á °èȹÀ¸·Î À̾îÁý´Ï´Ù.

Â÷¼¼´ë ´ç´¢º´ Ä¡·á ¹× ¾à¹°Àü´Þ ½ÃÀå µ¿Çâ :

¼¼°è ½ÃÀåÀº ÁÖ·Î ´ëÁßµé »çÀÌ¿¡¼­ ´ç´¢º´, ƯÈ÷ 2Çü ´ç´¢º´ÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹è°æ¿¡´Â °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°ü Áõ°¡, ÁÂ½Ä »ýȰ½À°ü, ½ÅüȰµ¿ °¨¼Ò µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó °³ÀÎÀÇ ´ÏÁî, ¶óÀÌÇÁ½ºÅ¸ÀÏ, Ä¡·á ¸ñÇ¥¿¡ µû¶ó ¸ÂÃãÈ­µÈ ȯÀÚ Áß½É Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¦Ç° º¸±ÞÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½º¸¶Æ® Àν¶¸° Ææ, Æó¼âÇü ·çÇÁ ½Ã½ºÅÛ, ºÎÀÛ¿ëÀÌ ÀûÀº À̽ÄÇü ±â±â °³¹ß µî Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀÌ ½ÃÀå¿¡ Ȱ·ÂÀ» ºÒ¾î³Ö°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Àúħ½ÀÀûÀ̰í ÅëÁõÀÌ ÀûÀº Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ °³ÀεéÀÇ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀåÀÇ Áß¿äÇÑ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·áºñ Áõ°¡¿Í °¡Ä¡ ±â¹Ý ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½É Áõ°¡µµ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÅÈï ±¹°¡ ½ÃÀå¿¡¼­´Â ºñ¿ë ¾ïÁ¦, ÀÎÁöµµ ºÎÁ·, Á¦Ç° ´Ù¾ç¼º ºÎÁ· µîÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¹Ý´ë·Î, ¿¹¹æ ÀÇ·á ¹× Á¶±â °³ÀÔ¿¡ ´ëÇÑ Á¤ºÎÀÇ ¿ìÈ£ÀûÀÎ ³ë·Â°ú »óȯ Á¤Ã¥ÀÇ ½ÃÇàÀº ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ Àü¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, ¸¸¼ºÁúȯ¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡´Â ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ½ÃÀå¿¡ ±â¿©ÇÏ´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ±Þ¼ÓÇÑ µµ½ÃÈ­, ÀüÅëÀûÀÎ ´ç´¢º´ Ä¡·á¿¡ µû¸¥ ÇÕº´Áõ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¿ø°ÝÀÇ·á ¹× µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÇ Ã¤Åà Áõ°¡, °¡Ã³ºÐ ¼Òµæ ¼öÁØ Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) Ȱµ¿ µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ Â÷¼¼´ë ´ç´¢º´ Ä¡·á¡¤¾à¹°Àü´Þ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : Àα¸Åë°è

Á¦8Àå ½ÃÀå ³»¿ª : ÀûÀÀÁõº°

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦11Àå ÃËÁø¿äÀΡ¤¾ïÁ¦¿äÀΡ¤±âȸ

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global next generation diabetes therapy and drug delivery market size reached USD 11.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 37.0 Billion by 2033, exhibiting a growth rate (CAGR) of 13.52% during 2025-2033. The rising prevalence of diabetes, particularly type-2 diabetes, continual technological advancements, and the growing geriatric population represent some of the key factors driving the market.

Next generation diabetes therapy and drug delivery procedure focuses on the introduction of insulin into the patient's body in a minimally invasive manner to reduce the risk of skin irritation from frequent needle usage. This patient-friendly approach aims to effectively manage the disease while reducing healthcare costs by utilizing innovative technologies including wearable sensors, micro-needles, and inhalable insulin. Advanced therapies, such as continuous glucose monitoring systems (CGMS), artificial pancreas, and insulin patches, are also employed to improve blood sugar level management that minimize the risks of diabetic-related complications. In addition, the procedure facilitates easy calculation of the dose volume, checking the blood glucose levels in real-time, and delivers insulin into the body painlessly, which, in turn, helps to maintain the dosage time. Some of the advantages of this therapy and drug delivery practice includes improved patient outcomes, enhanced treatment efficiency, and minimized burden of diabetes management for patients, leading to more targeted treatment plans.

Next Generation Diabetes Therapy and Drug Delivery Market Trends:

The global market is primarily driven by the rising prevalence of diabetes, particularly type-2 diabetes, among the masses. This can be attributed to the increasing consumption of unhealthy diets, sedentary lifestyles and reduced physical activity. In line with this, the augmenting demand for personalized and patient-centric care according to individual needs, lifestyle, and treatment goals is resulting in a higher product uptake. Moreover, continual technological advancements, such as the development of smart insulin pens, closed-loop systems, and implantable devices with fewer side effects, is providing an impetus to the market. In addition to this, the increasing emphasis on minimally invasive and pain-free treatment options among individuals is also acting as a significant growth-inducing factor for the market. The market is further driven by the increasing healthcare expenditure, along with an enhanced focus on value-based medical care solutions. However, the growing cost restrains, lack of awareness and less variability in products in the developing regions are acting as major growth-restraining factors for the market. Conversely, the implementation of favorable government initiatives and reimbursement policies regarding preventive healthcare and early intervention is creating a positive outlook for the market. Apart from this, the growing geriatric population that is more susceptible to developing chronic diseases is impacting the market favorably. Some of the other factors contributing to the market include rapid urbanization, increasing awareness regarding the associated complications of traditional diabetes treatment, rising adoption of telehealth and digital health solutions, inflating disposable income levels and extensive research and development (R&D) activities conducted by key players.

Key Market Segmentation:

Product Type Insights:

Demographic Insights:

Indication Insights:

End User Insights:

Regional Insights:

Competitive Landscape:

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Next Generation Diabetes Therapy and Drug Delivery Market

6 Market Breakup by Product Type

7 Market Breakup by Demographic

8 Market Breakup by Indication

9 Market Breakup by End User

10 Market Breakup by Region

11 Drivers, Restraints, and Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â